BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 36707972)

  • 1. Comparison of the sensitivity of different criteria to select lung cancer patients for screening in a cohort of German patients.
    Walter J; Kauffmann-Guerrero D; Muley T; Reck M; Fuge J; Günther A; Majeed RW; Savai R; Koch I; Dinkel J; Schneider C; Senghas K; Kobinger S; Manapov F; Thomas M; Kahnert K; Winter H; Behr J; Tammemägi M; Tufman A
    Cancer Med; 2023 Apr; 12(7):8880-8896. PubMed ID: 36707972
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Sensitivity of US Preventive Services Task Force and PLCOm2012 lung cancer screening eligibility criteria in individuals with lung cancer in South Dakota self-reporting as Indigenous and non-Indigenous.
    Tammemägi MC; Cina K; Kitts AKB; Koop D; Petereit MA; Sargent M; Petereit DG
    Cancer; 2023 Dec; 129(24):3894-3904. PubMed ID: 37807694
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Addressing Sex Disparities in Lung Cancer Screening Eligibility: USPSTF vs PLCOm2012 Criteria.
    Pasquinelli MM; Tammemägi MC; Kovitz KL; Durham ML; Deliu Z; Guzman A; Rygalski K; Liu L; Koshy M; Finn P; Feldman LE
    Chest; 2022 Jan; 161(1):248-256. PubMed ID: 34252436
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Race & sex disparities related to low-dose computed tomography lung cancer screening eligibility criteria: A lung cancer cases review.
    Williams RM; Kareff SA; Sackstein P; Roy T; Luta G; Kim C; Taylor KL; Tammemägi MC
    Lung Cancer; 2022 Jul; 169():55-60. PubMed ID: 35644087
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Risk prediction models for selection of lung cancer screening candidates: A retrospective validation study.
    Ten Haaf K; Jeon J; Tammemägi MC; Han SS; Kong CY; Plevritis SK; Feuer EJ; de Koning HJ; Steyerberg EW; Meza R
    PLoS Med; 2017 Apr; 14(4):e1002277. PubMed ID: 28376113
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Risk prediction models versus simplified selection criteria to determine eligibility for lung cancer screening: an analysis of German federal-wide survey and incidence data.
    Hüsing A; Kaaks R
    Eur J Epidemiol; 2020 Oct; 35(10):899-912. PubMed ID: 32594286
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Risk Prediction Model Versus United States Preventive Services Task Force Lung Cancer Screening Eligibility Criteria: Reducing Race Disparities.
    Pasquinelli MM; Tammemägi MC; Kovitz KL; Durham ML; Deliu Z; Rygalski K; Liu L; Koshy M; Finn P; Feldman LE
    J Thorac Oncol; 2020 Nov; 15(11):1738-1747. PubMed ID: 32822843
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Risk Model-Based Lung Cancer Screening and Racial and Ethnic Disparities in the US.
    Choi E; Ding VY; Luo SJ; Ten Haaf K; Wu JT; Aredo JV; Wilkens LR; Freedman ND; Backhus LM; Leung AN; Meza R; Lui NS; Haiman CA; Park SL; Le Marchand L; Neal JW; Cheng I; Wakelee HA; Tammemägi MC; Han SS
    JAMA Oncol; 2023 Dec; 9(12):1640-1648. PubMed ID: 37883107
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Economic impact of using risk models for eligibility selection to the International lung screening Trial.
    Cressman S; Weber MF; Ngo PJ; Wade S; Behar Harpaz S; Caruana M; Tremblay A; Manser R; Stone E; Atkar-Khattra S; Karikios D; Ho C; Fernandes A; Yi Weng J; McWilliams A; Myers R; Mayo J; Yee J; Yuan R; Marshall HM; Fong KM; Lam S; Canfell K; Tammemägi MC
    Lung Cancer; 2023 Feb; 176():38-45. PubMed ID: 36592498
    [TBL] [Abstract][Full Text] [Related]  

  • 10. USPSTF2013 versus PLCOm2012 lung cancer screening eligibility criteria (International Lung Screening Trial): interim analysis of a prospective cohort study.
    Tammemägi MC; Ruparel M; Tremblay A; Myers R; Mayo J; Yee J; Atkar-Khattra S; Yuan R; Cressman S; English J; Bedard E; MacEachern P; Burrowes P; Quaife SL; Marshall H; Yang I; Bowman R; Passmore L; McWilliams A; Brims F; Lim KP; Mo L; Melsom S; Saffar B; Teh M; Sheehan R; Kuok Y; Manser R; Irving L; Steinfort D; McCusker M; Pascoe D; Fogarty P; Stone E; Lam DCL; Ng MY; Vardhanabhuti V; Berg CD; Hung RJ; Janes SM; Fong K; Lam S
    Lancet Oncol; 2022 Jan; 23(1):138-148. PubMed ID: 34902336
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison Between the 2021 USPSTF Lung Cancer Screening Criteria and Other Lung Cancer Screening Criteria for Racial Disparity in Eligibility.
    Pu CY; Lusk CM; Neslund-Dudas C; Gadgeel S; Soubani AO; Schwartz AG
    JAMA Oncol; 2022 Mar; 8(3):374-382. PubMed ID: 35024781
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Analysis of lung cancer risk model (PLCO
    Lebrett MB; Balata H; Evison M; Colligan D; Duerden R; Elton P; Greaves M; Howells J; Irion K; Karunaratne D; Lyons J; Mellor S; Myerscough A; Newton T; Sharman A; Smith E; Taylor B; Taylor S; Walsham A; Whittaker J; Barber PV; Tonge J; Robbins HA; Booton R; Crosbie PAJ
    Thorax; 2020 Aug; 75(8):661-668. PubMed ID: 32631933
    [TBL] [Abstract][Full Text] [Related]  

  • 13. 'Reduced' HUNT model outperforms NLST and NELSON study criteria in predicting lung cancer in the Danish screening trial.
    Røe OD; Markaki M; Tsamardinos I; Lagani V; Nguyen OTD; Pedersen JH; Saghir Z; Ashraf HG
    BMJ Open Respir Res; 2019; 6(1):e000512. PubMed ID: 31803478
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Identifying high-risk individuals for lung cancer screening: Going beyond NLST criteria.
    Fu M; Travier N; Martín-Sánchez JC; Martínez-Sánchez JM; Vidal C; Garcia M;
    PLoS One; 2018; 13(4):e0195441. PubMed ID: 29621354
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Selecting High-Risk Individuals for Lung Cancer Screening: A Prospective Evaluation of Existing Risk Models and Eligibility Criteria in the German EPIC Cohort.
    Li K; Hüsing A; Sookthai D; Bergmann M; Boeing H; Becker N; Kaaks R
    Cancer Prev Res (Phila); 2015 Sep; 8(9):777-85. PubMed ID: 26076698
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Protocol and Rationale for the International Lung Screening Trial.
    Lim KP; Marshall H; Tammemägi M; Brims F; McWilliams A; Stone E; Manser R; Canfell K; Weber M; Connelly L; Bowman RV; Yang IA; Fogarty P; Mayo J; Yee J; Myers R; Atkar-Khattra S; Lam DCL; Rosell A; Berg CD; Fong KM; Lam S;
    Ann Am Thorac Soc; 2020 Apr; 17(4):503-512. PubMed ID: 32011914
    [No Abstract]   [Full Text] [Related]  

  • 17. Performance of Risk Factor-Based Guidelines and Model-Based Chest CT Lung Cancer Screening in World Trade Center-Exposed Fire Department Rescue/Recovery Workers.
    Cleven KL; Vaeth B; Zeig-Owens R; Colbeth HL; Jaber N; Schwartz T; Weiden MD; Markowitz SB; Silvestri GA; Prezant DJ
    Chest; 2021 May; 159(5):2060-2071. PubMed ID: 33279511
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Disparities of National Lung Cancer Screening Guidelines in the US Population.
    Han SS; Chow E; Ten Haaf K; Toumazis I; Cao P; Bastani M; Tammemagi M; Jeon J; Feuer EJ; Meza R; Plevritis SK
    J Natl Cancer Inst; 2020 Nov; 112(11):1136-1142. PubMed ID: 32040195
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Assessing Different Approaches to Leveraging Historical Smoking Exposure Data to Better Select Lung Cancer Screening Candidates: A Retrospective Validation Study.
    Kats DJ; Adie Y; Tlimat A; Greco PJ; Kaelber DC; Tarabichi Y
    Nicotine Tob Res; 2021 Aug; 23(8):1334-1340. PubMed ID: 32974635
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cost-Effectiveness Analysis of Lung Cancer Screening in the United States: A Comparative Modeling Study.
    Criss SD; Cao P; Bastani M; Ten Haaf K; Chen Y; Sheehan DF; Blom EF; Toumazis I; Jeon J; de Koning HJ; Plevritis SK; Meza R; Kong CY
    Ann Intern Med; 2019 Dec; 171(11):796-804. PubMed ID: 31683314
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.